These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37337707)

  • 1. An MMAE-loaded PDL1 active targeting nanomedicine for the precision treatment of colon cancer.
    Zhang Z; Zhang H; Cui L; Wang X; Wang D; Liu Z; Zhang X; Tang Z
    Biomater Sci; 2023 Jul; 11(15):5195-5204. PubMed ID: 37337707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation of an Ultrahigh-DAR PDL1 monoclonal antibody-polymeric-SN38 conjugate for precise colon cancer therapy.
    Zhang H; Sun J; Zhang Y; Zhang Z; Wang X; Liu Z; Zhang X; Tang Z; Chen X
    Biomaterials; 2023 Oct; 301():122285. PubMed ID: 37619265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer.
    Li Z; Wang M; Yu D; Luo W; Fang J; Huang C; Yao X
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):61-72. PubMed ID: 31037333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organic-Solvent-Free "Lego-Like" Modular Preparation of Fab-Nondestructive Antibody-Drug Conjugates with Ultrahigh Drug-to-Antibody Ratio.
    Liu Z; Zhang H; Sun J; Zheng M; Cui L; Zhang Y; Cheng J; Tang Z; Chen X
    Adv Mater; 2023 Nov; 35(46):e2300377. PubMed ID: 37532247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies.
    Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR
    Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy.
    Li Z; Wang M; Yao X; Luo W; Qu Y; Yu D; Li X; Fang J; Huang C
    Target Oncol; 2019 Feb; 14(1):93-105. PubMed ID: 30635821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bivalent EGFR-Targeting DARPin-MMAE Conjugates.
    Karsten L; Janson N; Le Joncour V; Alam S; Müller B; Tanjore Ramanathan J; Laakkonen P; Sewald N; Müller KM
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
    Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
    Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
    Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
    J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Payload-Binding Fab Fragments Increase the Therapeutic Index of MMAE Antibody-Drug Conjugates.
    Bordeau BM; Nguyen TD; Polli JR; Chen P; Balthasar JP
    Mol Cancer Ther; 2023 Apr; 22(4):459-470. PubMed ID: 36723609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
    Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
    J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer.
    Li H; Yu C; Jiang J; Huang C; Yao X; Xu Q; Yu F; Lou L; Fang J
    Cancer Biol Ther; 2016 Apr; 17(4):346-54. PubMed ID: 26853765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
    Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
    Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma.
    Munekage E; Serada S; Tsujii S; Yokota K; Kiuchi K; Tominaga K; Fujimoto M; Kanda M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
    Neoplasia; 2021 Sep; 23(9):939-950. PubMed ID: 34332450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery.
    Buckel L; Savariar EN; Crisp JL; Jones KA; Hicks AM; Scanderbeg DJ; Nguyen QT; Sicklick JK; Lowy AM; Tsien RY; Advani SJ
    Cancer Res; 2015 Apr; 75(7):1376-1387. PubMed ID: 25681274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and anti-cancer evaluation of promiximab-MMAE, an anti-CD56 antibody drug conjugate, in small cell lung cancer cell line xenograft models.
    Yu L; Yao Y; Wang Y; Zhou S; Lai Q; Lu Y; Liu Y; Zhang R; Wang R; Liu C; Gou L; Chen X; Yu Y; Chen Q; Yang J
    J Drug Target; 2018 Dec; 26(10):905-912. PubMed ID: 29630426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses.
    Ballesteros-Briones MC; Martisova E; Casales E; Silva-Pilipich N; Buñuales M; Galindo J; Mancheño U; Gorraiz M; Lasarte JJ; Kochan G; Escors D; Sanchez-Paulete AR; Melero I; Prieto J; Hernandez-Alcoceba R; Hervas-Stubbs S; Smerdou C
    Mol Ther; 2019 Nov; 27(11):1892-1905. PubMed ID: 31563534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.
    Yao HP; Feng L; Weng TH; Hu CY; Suthe SR; Mostofa AGM; Chen LH; Wu ZG; Wang WL; Wang MH
    Mol Pharm; 2018 Aug; 15(8):3260-3271. PubMed ID: 29944378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Site-Specific Cleavage Improves the Antitumor Efficacy of Antibody-Drug Conjugates.
    Xu K; Han J; Yang L; Cao L; Li S; Hong Z
    Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.